Acurx Pharmaceuticals, Inc. (ACXP)
1.43
+0.01
(+0.70%)
USD |
NASDAQ |
Sep 08, 16:00
1.435
0.00 (0.00%)
Pre-Market: 20:00
Acurx Pharmaceuticals EPS Diluted (Quarterly) : -0.5292 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.5292 |
| March 31, 2026 | -0.6184 |
| December 31, 2025 | -0.6722 |
| September 30, 2025 | -1.226 |
| June 30, 2025 | -1.887 |
| March 31, 2025 | -0.1072 |
| December 31, 2024 | -3.267 |
| September 30, 2024 | -0.1724 |
| June 30, 2024 | -0.2605 |
| March 31, 2024 | -0.283 |
| December 31, 2023 | -0.3799 |
| September 30, 2023 | -0.2395 |
| Date | Value |
|---|---|
| June 30, 2023 | -0.2827 |
| March 31, 2023 | -0.2494 |
| December 31, 2022 | -0.2809 |
| September 30, 2022 | -0.3177 |
| June 30, 2022 | -0.2553 |
| March 31, 2022 | -0.2609 |
| December 31, 2021 | -0.2572 |
| September 30, 2021 | -0.4584 |
| June 30, 2021 | -0.4038 |
| March 31, 2021 | -0.1487 |
| June 30, 2020 | -0.0921 |
| March 31, 2020 | -0.129 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.254M |
| Total Expenses (Quarterly) | 2.254M |
| Enterprise Value | -3.959M |
| Earnings Yield | -213.0% |
| Normalized Earnings Yield | -212.96 |